| Alternative Names | SIGLEC3, gp67 |
| Source | Human CD33 Protein; His Tag (GM-88735RP) is expressed from human 293 cells (HEK-293). It contains AA Asp 18 - His 259 (Accession # AAH28152.1). This protein carries a His tag at the C-terminus. |
| Purity | > 95% as determined by SDS-PAGE |
| Endotoxin | < 1 EU/μg, determined by LAL gel clotting assay |
| Predicted Mol Mass | 27.6 kDa |
| Formulation | Supplied as a 0.2 μm filtered solution of PBS, pH7.2-7.4. |
| Description | CD33 protein, full name Cluster of Differentiation 33, also known as Siglec-3 (Sialic acid-binding immunoglobulin-type lectin-3), is an important cell surface transmembrane glycoprotein and a member of the Siglec family of immunomodulatory receptors. CD33 protein plays a crucial role in regulating myeloid cell function by binding to sialic acid-containing glycans on the cell surface, thereby mediating cell-cell interactions, inhibiting cell activation, and modulating inflammatory responses and immune homeostasis in normal physiological conditions. Currently, CD33-targeted therapeutic strategies have shown significant clinical promise, with the antibody-drug conjugate (ADC) Gemtuzumab Ozogamicin (Mylotarg®) having been approved for the treatment of newly diagnosed or relapsed/refractory CD33-positive AML. In summary, CD33 protein plays a pivotal role in leukemogenesis and immune evasion in hematological cancers, and holds great significance for understanding tumor immunology, identifying myeloid leukemia biomarkers, developing novel targeted immunotherapies such as ADCs, BiTEs, and CAR-T, and evaluating patient prognosis in AML and other myeloid malignancies. |
| Alternative Names | SIGLEC3, gp67 |
| Source | Human CD33 Protein; His Tag (GM-88735RP) is expressed from human 293 cells (HEK-293). It contains AA Asp 18 - His 259 (Accession # AAH28152.1). This protein carries a His tag at the C-terminus. |
| Purity | > 95% as determined by SDS-PAGE |
| Endotoxin | < 1 EU/μg, determined by LAL gel clotting assay |
| Predicted Mol Mass | 27.6 kDa |
| Formulation | Supplied as a 0.2 μm filtered solution of PBS, pH7.2-7.4. |
| Description | CD33 protein, full name Cluster of Differentiation 33, also known as Siglec-3 (Sialic acid-binding immunoglobulin-type lectin-3), is an important cell surface transmembrane glycoprotein and a member of the Siglec family of immunomodulatory receptors. CD33 protein plays a crucial role in regulating myeloid cell function by binding to sialic acid-containing glycans on the cell surface, thereby mediating cell-cell interactions, inhibiting cell activation, and modulating inflammatory responses and immune homeostasis in normal physiological conditions. Currently, CD33-targeted therapeutic strategies have shown significant clinical promise, with the antibody-drug conjugate (ADC) Gemtuzumab Ozogamicin (Mylotarg®) having been approved for the treatment of newly diagnosed or relapsed/refractory CD33-positive AML. In summary, CD33 protein plays a pivotal role in leukemogenesis and immune evasion in hematological cancers, and holds great significance for understanding tumor immunology, identifying myeloid leukemia biomarkers, developing novel targeted immunotherapies such as ADCs, BiTEs, and CAR-T, and evaluating patient prognosis in AML and other myeloid malignancies. |
